Inside this issue:
Retina Research Initiative
The New York Eye & Ear Infirmary Research Initiative for Prevention and Cure was established through a grant from the New York Eye & Ear Infirmary, corporate sponsors, investors and patron donations to develop new comprehensive technologies for early diagnosis, prevention and treatment of eye disease. Our research team plays a prominent role in many major ophthalmic clinical trials and proudly dedicate ourselves to serve the needs of our patients.
Ask your doctor for more information on new and innovative research treatments for retinal, uveitis, glaucoma and childhood vision conditions!
The Age-Related Eye Disease Study 2 (AREDS2) is a multi-center, randomized trial designed to assess the effects of oral supplementation of macular xanthophylls (lutein and zeaxanthin) and/or long-chain omega-3 fatty acids (docosahexaenoic acid) [DHA] and eicosapentaenoic acid [EPA] ) on the progression to advanced age-related macular degeneration (AMD). An additional goal of the study is to assess whether forms of the AREDS nutritional supplement with reduced zinc and/or no beta-carotene works as well as the original supplement in reducing the risk of progression to advanced AMD.
For more information, contact your study coordinators: Anita Ou at 212-979-4672 and Jenny Gallardo at 212-614-8386.
To compare visual acuity outcome among 3 groups of participants: those who are randomly assigned to receive standard care and those randomly assigned to receive one of two doses of intravitreal injection(s) of triamcinolone acetonide for treatment of macular edema associated with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).
For more information, contact: Katy Tai at 212-979-4251.
This trial will explore the safety and efficacy of intravitreous injections of Macugen® (pegaptanib sodium) when given every 6 weeks for 48 weeks in subjects with exudative maculopathy who, after previous treatment regimen, have improved based upon clinical and anatomical (OCT) findings as determined by the investigator. Macugen® will be provided at no cost to you during this study.
For more information, contact your study coordinator: Peggy Guerrero, MD, at 212-979-4671.
The primary objectives of the MacTel Study are to enroll subjects with Macular Telangiectasia of the group 2 type, to document structural and functional changes, and to follow subjects over a period of up to five (5) years. Data will be analyzed to identify potential risk factors and related outcomes.
For more information, contact your study coordinator: Anita Ou at 212-979-4672.
Find out how you can empower yourself and help others by sharing your story. For patients receiving treatment for UVEITIS or AMD at NYEE or a family member interested in learning more, please call 212-979-4390.
This study tests the Posurdex steroid implant, which is given by injection in the office (minor procedure as opposed to surgery, as necessary for the Retisert implant) in patients with uveitis at the back of the eye. This is an international trial and we have started enrolling patients. All patients eligible for this study will receive the steroid implant, study-related eye exams and travel arrangements at no cost.
For more information, please call your study coordinator: Julie Paa at 212-979-4024.
This studies the use of Confocal Microscopy to determine if KPs are homogenous throughout the cornea in patients with Sarcoidosis- Associated Uveitis. The study will help determine if KPs are different in acute and chronic disease states, which may have a diagnostic significance in identifying the etiology of Uveitis.
For more information, please contact Dr. Samir Tari, 212-979-4919.
If you have type 1 or type 2 diabetes and have been diagnosed with swelling in the back of the eye or macular edema in at least one eye, you may be eligible to participate in a research study. This study is testing an investigational drug treatment called Dexamethasone. As a participant, you will receive study related medication and care, lab tests, and eye examination at no cost to you. You must be 18 years or older and have developed macular edema associated with diabetic retinopathy to qualify.
For more information, call your study coordinator: Julie Paa at 212-979-4024.